**Kateryna Levada 1, Alexander Omelyanchik 1, Valeria Rodionova 1,2, Ralf Weiskirchen <sup>3</sup> and Matthias Bartneck 4,\***


Received: 19 September 2019; Accepted: 15 October 2019; Published: 19 October 2019

**Abstract:** Chronic liver injury can be induced by viruses, toxins, cellular activation, and metabolic dysregulation and can lead to liver fibrosis. Hepatic fibrosis still remains a major burden on the global health systems. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are considered the main cause of liver fibrosis. Hepatic stellate cells are key targets in antifibrotic treatment, but selective engagement of these cells is an unresolved issue. Current strategies for antifibrotic drugs, which are at the critical stage 3 clinical trials, target metabolic regulation, immune cell activation, and cell death. Here, we report on the critical factors for liver fibrosis, and on prospective novel drugs, which might soon enter the market. Apart from the current clinical trials, novel perspectives for anti-fibrotic treatment may arise from magnetic particles and controlled magnetic forces in various different fields. Magnetic-assisted techniques can, for instance, enable cell engineering and cell therapy to fight cancer, might enable to control the shape or orientation of single cells or tissues mechanically. Furthermore, magnetic forces may improve localized drug delivery mediated by magnetism-induced conformational changes, and they may also enhance non-invasive imaging applications.

**Keywords:** liver fibrosis; magnetic fields; nanomedicines; immune cells; macrophages; hepatic stellate cells; RNA-based medicines; drug delivery; magnetic nanoparticles
